Diabetes Care Devices Market Size & Share 2026-2035

Diabetes Care Devices Market Size

The global diabetes care devices market was estimated at USD 59.2 billion in 2025. The market is expected to grow from USD 65.9 billion in 2026 to USD 188.8 billion in 2035, at a CAGR of 12.4% during the forecast period, according to the latest report published by Global Market Insights Inc. The market is driven by numerous factors, such as the growing prevalence of diabetes across the world, increasing demand for minimally invasive and wearable devices, among other factors.

Diabetes care devices refer to a range of medical devices designed to help individuals with diabetes manage their condition effectively. These devices play a crucial role in monitoring blood glucose levels, administering insulin, and overall diabetes management. Major companies in the industry include F. Hoffmann-La Roche, Abbott Laboratories, Ascensia Diabetes Care Holdings, LifeScan, and Dexcom

The market has increased from USD 43.8 billion in 2022 and reached USD 53.5 billion in 2024, with a historic growth rate of 10.5%. The growth of the global diabetes care devices market is highly attributed to the rising prevalence of diabetes across the globe. For instance, as per the estimates from the International Diabetes Federation (IDF), 537 million people were living with diabetes worldwide in 2021. This number is projected to reach 643 million in 2030 and then to 783 million in 2045. Thus, this increasing prevalence of diabetes among the population necessitates technologically advanced diabetes care devices for monitoring blood glucose levels among the affected patients and for the administration of insulin, thereby positively contributing to the growth of the market. 

The growing elderly population worldwide is one of the significant catalysts for the upward trajectory of the market. For instance, according to data provided by the United Nations, it is projected that the global population aged 65 years and older will reach around 1.5 billion by 2050, representing 16% of the world’s population. Moreover, according to data from the Population Reference Bureau, individuals in the U.S. aged 65 and older are projected to reach 82 million by 2050, up from 58 million in 2022. The population of this demographic is more likely to have chronic disease conditions such as diabetes, which often require frequent blood glucose monitoring, in turn stimulating the need for reliable and efficient glucose monitors. Therefore, as the population ages, so does the risk of diabetes among the demographic, thereby fostering the growth of the market.

Additionally, increasing investments by public and private organizations are significantly driving growth in the diabetes care devices market, as stakeholders prioritize prevention, early diagnosis, and long-term disease management. Governments and healthcare bodies are actively funding large-scale programs aimed at reducing diabetes burden and associated healthcare costs. The National Diabetes Prevention Program (NDPP), led by the CDC, focuses on individuals with prediabetes by connecting them with certified lifestyle coaches through local and digital platforms to promote weight loss, physical activity, and behavioral changes. Such initiatives not only enhance awareness and early intervention but also indirectly boost demand for diabetes monitoring and management devices, including glucose monitoring systems and insulin delivery solutions. Additionally, private sector investments in digital health, wearable technologies, and connected devices further complement these efforts, supporting the expansion of advanced diabetes care ecosystems and accelerating market growth.

Diabetes Care Devices Market Trends

The technological advancement of diabetes care devices is one of the major trends accelerating the market forward. Many companies in this market are investing in the development of diabetes care devices that are cost-effective, painless, and provide highly effective and reliable results for diabetic patients.

• For instance, Dexcom's G7 continuous glucose monitor is one of the most precise sensors of the company, suitable for patients with type 1, type 2, or gestational diabetes. This sensor is 60% smaller than its predecessor, the G6. It provides real-time data directly to smartwatches or smartphones, eliminating the need for fingerstick tests.
• Moreover, established players in the market are focusing on product launches, acquisitions, regulatory approvals, and partnerships in order to increase their customer base and market presence across the emerging and developed countries of the world.
• For instance, in May 2022, Abbott launched FreeStyle Libre 3, the 14-day sensor. This sensor is suitable for patients aged four and above, offering continuous blood glucose monitoring. This sensor is intended to be worn on the upper arm and transmits to a smartphone application.
• Additionally, SMBG devices have also become more portable and comfortable due to compact and ergonomic designs.
• For instance, the CONTOUR NEXT ONE meter by Ascensia Diabetes Care is equipped with the Second Chance Sampling feature, which enables patients to add more blood to the test strip if the first sample didn't fill the required amount. This cuts down on wasted lancets and test strips, saves on finger pricks, and increases the user's comfort with the device, thereby enhancing usability.
• Thus, these technological advancements are positively contributing to the adoption among the patients, fostering market growth.

Diabetes Care Devices Market Analysis

Based on the product, the market is segmented into devices and consumables. The devices segment is further bifurcated into blood glucose monitoring devices and insulin delivery devices. The devices segment was valued at USD 40.5 billion in 2025 and is projected to reach USD 130.9 billion by 2035, growing at a CAGR of 12.6%.

• The devices segment represented the dominating product category in the diabetes care devices market, driven by the rising adoption of advanced technologies such as blood glucose monitoring devices, insulin pumps, and insulin pens. Blood glucose monitoring devices, particularly continuous glucose monitoring (CGM) systems, are widely utilized due to their ability to provide real-time glucose insights, enabling better glycemic control and reducing the risk of complications. Insulin pumps and pens further enhance treatment efficiency by offering precise dosing, improved convenience, and enhanced patient adherence. The increasing prevalence of diabetes, coupled with the growing shift toward self-management and home-based care, continues to drive demand for these devices, reinforcing their leadership position in the market.
• A range of advanced and commercially successful products highlights the strength and diversity of the devices segment. For instance, Dexcom G6/G7 and Abbott FreeStyle Libre systems dominate the CGM market with real-time glucose monitoring and smartphone integration capabilities. In insulin delivery, leading products such as the Medtronic MiniMed 780G and Tandem t:slim X2 insulin pumps offer advanced automated insulin delivery with algorithm-driven dosing adjustments.
• Additionally, smart insulin pens like Medtronic InPen and Novo Nordisk NovoPen 6/Echo Plus provide dose tracking, Bluetooth connectivity, and integration with diabetes management apps. These product innovations highlight the ongoing shift toward connected, patient-centric, and technology-driven diabetes care, further strengthening the leadership of the devices segment in the market.
• The consumables segment is projected to expand at a 12% CAGR to reach USD 57.9 billion by 2035. The consumables segment plays a critical supporting role in market expansion due to the recurring demand associated with diabetes management. This segment includes test strips, lancets, pen needles, testing strips, and syringes that are essential for the daily functioning of glucose monitoring devices and insulin delivery systems. The high replacement rate of these products ensures consistent revenue generation and long-term market sustainability. Additionally, advancements in consumable design, such as longer-lasting sensors, minimally invasive lancets, and improved infusion sets, are enhancing patient comfort and usability. The growing installed base of diabetes care devices, combined with the need for continuous monitoring and therapy, is expected to drive steady growth in the consumables segment.

Based on end use, the diabetes care devices market is segmented into hospitals, ambulatory surgery centers, diagnostic centers, home care, and other end users. The home care segment dominates the market with a revenue of around USD 26 billion in 2025.

• The home care segment dominates the diabetes care devices market, driven by the growing emphasis on self-management, convenience, and long-term disease control. Patients increasingly rely on devices such as CGMs, insulin pens, and home-based monitoring systems to manage their condition independently. The rise of connected devices, telehealth, and remote monitoring solutions has further strengthened this segment, enabling continuous tracking and data sharing with healthcare providers. Additionally, the preference for minimally invasive, user-friendly devices supports sustained adoption in home settings
• The older population becomes more susceptible to diabetes, and many opt for home management to maintain independence and minimize healthcare visits. This demographic shift amplifies the demand for home care devices in the diabetes care market. Individuals aged 65 and above appreciate the convenience of using diabetes care devices at home. The rising geriatric population grappling with diabetes continues to expand the home care segment.
• Therefore, the increasing preference for home management of diabetes, especially among the elderly, is driving significant growth in the home-use diabetes care devices market.
• The hospitals segment is projected to expand at a 12.3% CAGR to reach USD 37.4 billion by 2035. Hospitals represent a significant end user segment due to their role in managing complex and critical diabetes cases, including patients requiring intensive insulin therapy and continuous glucose monitoring. These settings utilize advanced diabetes care devices such as insulin pumps and integrated monitoring systems to support inpatient care and emergency interventions. Hospitals also drive device adoption through clinical protocols and physician recommendations, particularly for newly diagnosed or high-risk patients requiring close supervision.
• The ambulatory surgery centers segment is projected to expand at a 10.9% CAGR to reach USD 13.5 billion by 2035. Ambulatory surgery centers are increasingly incorporating diabetes care devices to manage perioperative glycemic control in diabetic patients undergoing minor and outpatient procedures. The need for precise insulin management and real-time glucose monitoring during short-duration surgical interventions has led to the adoption of portable and easy-to-use devices. ASCs focus on efficiency and quick patient turnover, making compact and reliable diabetes management solutions highly relevant in these settings.
• The diagnostic centers segment is projected to expand at a 12.7% CAGR to reach USD 25.9 billion by 2035. Diagnostic centers primarily utilize diabetes care devices for screening, testing, and monitoring purposes. Blood glucose meters and point-of-care testing devices are widely used to support early diagnosis, routine check-ups, and monitoring of treatment effectiveness. These centers play a key role in preventive healthcare by facilitating early detection of diabetes and prediabetes, thereby contributing to increased demand for monitoring devices.
• The other end users segment is projected to expand at an 11.5% CAGR to reach USD 25.3 billion by 2035. It includes clinics, long-term care facilities, and rehabilitation centers, where diabetes care devices are used as part of routine patient management. These settings often cater to elderly populations and patients with comorbidities, requiring consistent glucose monitoring and insulin administration.

North America Diabetes Care Devices Market

The North America market accounted for a majority share of 41.9% in 2025 and is anticipated to show notable growth over the forecast period.

• The U.S. market was valued at USD 16.9 billion and USD 18.6 billion in 2022 and 2023, respectively. The market size reached USD 22.7 billion in 2025, growing from USD 20.5 billion in 2024, and is anticipated to grow at a CAGR of 12.2% from 2026 to 2035.
• The North America market is significantly driven by the growing prevalence of diabetes across the region, which continues to expand the patient population requiring long‑term disease management solutions. The increasing incidence of lifestyle-related risk factors such as obesity, sedentary behavior, and aging demographics has contributed to a substantial rise in diabetes cases. For instance, in 2021, according to the Centers for Disease Control and Prevention (CDC), approximately 38.4 million individuals in the U.S. were living with diabetes, of which 90–95% were affected by type 2 diabetes. This large and continuously growing patient pool is generating sustained demand for diabetes care devices, including blood glucose monitoring systems, insulin pumps, and insulin pens, aimed at improving glycemic control and minimizing long-term complications.
• Continuous technological advancements in diabetes care devices are accelerating market growth and adoption across North America. Innovations such as continuous glucose monitoring (CGM) systems, smart insulin pens, and automated insulin delivery systems are transforming diabetes management by offering real-time data insights, improved dosing accuracy, and enhanced patient convenience. The increasing integration of digital health technologies, including mobile applications, cloud connectivity, and AI-powered analytics, is enabling more personalized and proactive care.
• These advancements not only improve patient outcomes but also support healthcare providers in optimizing treatment plans, thereby reinforcing the adoption of advanced diabetes care devices across the region.

Europe Diabetes Care Devices Market

Europe accounted for a significant share of the global market and was valued at USD 16.6 billion in 2025.

• The Europe market is significantly driven by the rising prevalence of diabetes across the region, which continues to expand the population requiring continuous monitoring and management solutions. Increasing aging demographics, sedentary lifestyles, and growing incidence of obesity have contributed to a steady rise in diabetes cases. According to the International Diabetes Federation (IDF), the number of adults aged 20–79 years living with diabetes in Europe reached approximately 65.6 million in 2024, highlighting the substantial disease burden across the region. This large patient base is driving sustained demand for diabetes care devices such as blood glucose monitoring systems, insulin pumps, and insulin pens to ensure effective glycemic control and reduce complications.
• Furthermore, ongoing technological advancements in diabetes care devices are strongly supporting market growth across Europe. The increasing adoption of continuous glucose monitoring (CGM) systems, connected insulin delivery devices, and automated insulin delivery technologies is transforming diabetes management. These advancements enable real-time monitoring, enhanced dosing accuracy, and improved patient convenience. Additionally, the integration of digital health tools, including mobile applications and cloud-based platforms, allows for better data tracking and remote patient management. These innovations, combined with strong healthcare systems and increasing awareness of diabetes management, continue to drive the adoption of advanced diabetes care devices across the European market.

Asia Pacific Diabetes Care Devices Market

The Asia Pacific market accounted for a substantial share of the market and was valued at USD 13 billion in 2025.

• The Asia Pacific market is witnessing strong growth, supported by the rapidly increasing diabetes burden across populous and developing economies. Rising urbanization, changing dietary habits, and limited preventive care infrastructure are significantly contributing to the growing incidence of diabetes in the region. According to the International Diabetes Federation (IDF), the number of people living with diabetes in Southeast Asia is projected to increase by 73%, reaching approximately 185 million by 2050, highlighting the substantial future demand for disease management solutions. This expanding patient base is driving the need for scalable, accessible, and cost-effective diabetes care devices across both urban and rural healthcare settings.
• Furthermore, increasing investments by public and private organizations, along with rising demand for minimally invasive and wearable devices, are accelerating market development across Asia Pacific. Governments are strengthening healthcare infrastructure and launching large-scale diabetes management programs, while private players are investing in expanding device accessibility and affordability. At the same time, patients are increasingly shifting toward compact, minimally invasive, and wearable solutions such as continuous glucose monitors and patch-based insulin delivery systems that enable greater comfort and ease of use. This combination of investment-led expansion and evolving patient preferences is supporting deeper market penetration and sustained adoption of diabetes care devices across the region.

Latin America Diabetes Care Devices Market

The Latin America market is anticipated to exhibit remarkable growth during the analysis period.

• The Latin America market is growing steadily, driven by increasing government initiatives and the rising integration of digital health solutions across the region. Countries are focusing on strengthening healthcare systems and expanding access to chronic disease management programs, particularly for diabetes care. These initiatives are improving early diagnosis rates and facilitating the wider adoption of diabetes care devices, including glucose monitoring systems and insulin delivery solutions, across both public and private healthcare sectors.
• Digital health adoption is playing a crucial role in enhancing diabetes management and device accessibility in Latin America. The growing use of telemedicine platforms and mobile health applications is enabling improved patient engagement, remote monitoring, and continuous data tracking. These digital tools support better adherence to treatment regimens and allow healthcare providers to monitor patients in real time, thereby increasing the effectiveness and uptake of diabetes care devices, especially in remote and underserved regions.

Middle East and Africa Diabetes Care Devices Market

The Middle East and Africa market is expected to experience substantial growth over the analysis timeframe.

• The Middle East and Africa (MEA) market is witnessing steady growth, supported by improving healthcare infrastructure and increasing investments in advanced medical technologies. Countries within the region, particularly in the Gulf Cooperation Council (GCC), are focusing on modernizing healthcare systems and expanding access to specialized care. This is creating significant opportunities for the adoption of advanced diabetes care devices tailored to regional patient needs, including glucose monitoring systems and insulin delivery solutions. The ongoing development of healthcare facilities and increasing private sector participation are further contributing to market expansion across MEA.
• In addition, the rising focus on diabetes awareness and screening initiatives is positively influencing market growth. Governments and healthcare organizations across the region are launching programs aimed at early detection, prevention, and effective disease management. Initiatives such as national diabetes screening and awareness campaigns are encouraging individuals to monitor their glucose levels regularly, thereby increasing the demand for diabetes care devices. These efforts are also helping reduce undiagnosed cases and improving long-term disease management outcomes.

Diabetes Care Devices Market Share

• The top 5 players in the diabetes care devices industry, such as F. Hoffmann-La Roche, Abbott Laboratories, Ascensia Diabetes Care Holdings, LifeScan, and Dexcom, collectively hold a 22.4% share of the global market. These companies maintain their leadership through diverse product portfolios, strategic collaborations, regulatory approvals, and ongoing innovation. Abbott Laboratories stands out due to their comprehensive range of diabetes care devices, widely adopted in hospitals and diagnostic centers.
• Abbott Laboratories and Dexcom have strengthened their market positions through acquisitions and product launches. In September 2023, Abbott acquired Bigfoot Biomedical, a renowned developer of smart insulin management systems for individuals with diabetes. This acquisition united two industry leaders in distinct areas of diabetes care, including continuous glucose monitoring, which is estimated to reach USD 47.1 billion by 2034, and insulin dosing support. The strategic move enriched the company's product portfolio in diabetic care and bolstered revenue generation.
• Moreover, in March 2024, Dexcom introduced its newest CGM system, Dexcom ONE+, in Ireland. Dexcom ONE+ utilizes Dexcom's top-tier and highly accurate sensor design. This product launch bolstered the company's product portfolio in the Irish market and boosted the company's revenue.

Diabetes Care Devices Market Companies

A few of the prominent players operating in the global diabetes care devices industry include:

• Abbott Laboratories
• ARKRAY
• Ascensia Diabetes Care
• B. Braun Melsungen
• Becton Dickinson and Company
• Bionime
• DarioHealth
• Dexcom
• Dr. Reddy’s Laboratories
• Eli Lilly and Company
• F. Hoffmann-La Roche
• Insulet
• Medtronic
• Nova Biomedical
• Novo Nordisk
• Pendiq
• LifeScan
• Sanofi
• Sinocare
• Tandem Diabetes Care
• Ypsomed Holding

• Abbott Laboratories

Abbott is a global healthcare company with a diversified portfolio of medical devices, diagnostics, nutrition, and branded generic pharmaceuticals. The company is offering a range of products and solutions to help individuals manage their diabetes effectively. FreeStyle Libre is Abbott's flagship continuous glucose monitoring (CGM) system. It offers a factory-calibrated sensor that eliminates the need for routine fingerstick calibrations, providing real-time glucose readings and trend data.

• Ascensia Diabetes Care

Ascensia Diabetes Care specializes in diabetes management solutions. The company is renowned for its portfolio of blood glucose monitoring systems, particularly the CONTOUR brand, which is widely recognized for its accuracy and ease of use. In recent years, Ascensia has expanded its portfolio to include digital health solutions and continuous glucose monitoring (CGM) technologies, advancing personalized care options for diabetes management.

• B. Braun Melsungen

B. Braun Melsungen, a renowned player in the medical technology industry, also holds significance in the diabetes care devices market. While traditionally recognized for its expertise in infusion therapy and medical equipment, B. Braun has steadily expanded its portfolio to include innovative solutions for diabetes management. With more than 300 subsidiaries in 64 countries and a portfolio boasting 5,000 healthcare products, the company operates its business on a global scale.

Diabetes Care Devices Industry News:

• In September 2024, Dexcom made a strategic investment of USD 75 million in Oura, a leading health-tracking ring manufacturer, and formed a partnership to enable bi-directional data integration between Dexcom’s CGM and the Oura Ring. This collaboration enhanced Dexcom’s competitive advantage by integrating glucose data with broader health metrics for more personalized insights.
• In January 2024, Dexcom revealed its submission of the new Stelo glucose sensor to the FDA for review. Tailored by the continuous glucose monitor (CGM) maker, Stelo is intended for individuals with type 2 diabetes that do not require insulin. This strategic initiative is anticipated to position Dexcom with a competitive advantage in the market.
• In January 2024, Medtronic announced CE Mark approval for the MiniMed 780G system featuring Simplera Syn, a compact CGM that eliminates the need for fingerstick or overtape. With a simplified insertion process and smaller size, it enhances user experience while upholding glucose monitoring accuracy and reliability, marking a notable advancement for Medtronic.
• In March 2023, Astellas Pharma Inc. disclosed its partnership with Roche Diabetes Care Japan Co., Ltd. to collaboratively develop and commercialize the Accu-Chek Guide Me blood glucose monitoring system with enhanced accuracy. Additionally, the agreement involved integrating BlueStar, an FDA-cleared digital health solution for diabetes patients developed by Welldoc, Inc. and presently accessible in the U.S. and Canada. The primary objective of this collaboration was to enhance the accuracy of the product and attain a competitive edge in the market.

The global diabetes care devices market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Devices
  • Blood glucose monitoring devices
    • Self-monitoring blood glucose meters
    • Continuous glucose monitors
  • Insulin delivery devices
    • Insulin pumps
      • Tubed pumps
      • Tubeless pumps
    • Pens
      • Reusable
      • Disposable
    • Other insulin delivery devices
• Consumables
  • Testing strips
  • Lancets
  • Pen needles
    • Standard
    • Safety
  • Syringes
  • Insulin pump consumables

Market, By End Use

• Hospital
• Ambulatory surgical centers        
• Diagnostic centers
• Home care
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE